Announced details
Treatment of adenovirus infection associated with organ transplantation, including hematopoietic stem cell transplantation
The Company will receive the grant. Capital and personnel relationships: Not disclosed.
A national research and development agency responsible for administering research and development grants for orphan drugs and related products. Location, representative, capital and year established: Not disclosed.
Orphan drug designation; FY2026 research and development grant for orphan drugs and related products
Minister of Health, Labour and Welfare; National Institutes of Biomedical Innovation, Health and Nutrition
The impact on the Company’s consolidated results for the fiscal year ending December 2026 is expected to be immaterial.
The company does not address Contract Value / Offering price.
Ministry of Health, Labour and Welfare, “Orphan Drug Designation System”
| Item | Details |
|---|---|
| Names of Products / Services Covered | brincidofovir (injectable brincidofovir, IV BCV) |
| Counterparty | National Institutes of Biomedical Innovation, Health and Nutrition |
| Counterparty overview | A national research and development agency responsible for administering research and development grants for orphan drugs and related products. Location, representative, capital and year established: Not disclosed. |
| Relationship with the Company | The Company will receive the grant. Capital and personnel relationships: Not disclosed. |
| Applicable area | Treatment of adenovirus infection associated with organ transplantation, including hematopoietic stem cell transplantation |
| Award/certification name | Orphan drug designation; FY2026 research and development grant for orphan drugs and related products |
| Awarding / certifying body | Minister of Health, Labour and Welfare; National Institutes of Biomedical Innovation, Health and Nutrition |
| Impact on Business Performance | The impact on the Company’s consolidated results for the fiscal year ending December 2026 is expected to be immaterial. |
| Source | Ministry of Health, Labour and Welfare, “Orphan Drug Designation System” |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The grant is provided under a program designed to promote the research and development of products for intractable diseases with high unmet medical needs and small patient populations, while reducing the development cost burden.